Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: Possibility of a novel predictive factor for tamoxifen resistance

Breast Cancer Research and Treatment

Volumn 122, Issue 2, 2010, Pages 395-407

  Imachi, Hitomi ^a   Murao, Koji ^a   Dobashi, Hiroaki ^a   Bhuyan, Mohammad M ^b   Cao, Xueyuan ^c   Kontani, Keiichi ^a   Niki, Shoko ^a   Murazawa, Chisa ^a   Nakajima, Hiroo ^d   Kohno, Norio ^e   Yamashita, Hiroko ^f   Iwase, Hirotaka ^g   Hayashi, Shin Ichi ^h   Ishida, Toshihiko ^a   Yamauchi, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JILIN UNIVERSITY   (China)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e TOKYO MEDICAL UNIVERSITY   (Japan)

^f NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^g KUMAMOTO UNIVERSITY   (Japan)

^h TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Estrogen receptor; Menin; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR ALPHA; LUCIFERASE; METHIONINE; SMALL INTERFERING RNA; TAMOXIFEN; ANTIESTROGEN; ESTRADIOL; HYBRID PROTEIN; MEN1 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; RNA INTERFERENCE; TWO HYBRID SYSTEM; WESTERN BLOTTING; WILD TYPE; ADJUVANT CHEMOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; BREAST NEOPLASMS; CANCER STAGING; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROMOTER REGION; TIME; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANIMALS; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHEMOTHERAPY, ADJUVANT; COS CELLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN INTERACTION MAPPING; PROTO-ONCOGENE PROTEINS; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; TAMOXIFEN; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TWO-HYBRID SYSTEM TECHNIQUES; KAPLAN-MEIER ESTIMATE;

EID: 77955665779     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0581-0     Document Type: Article

References (58)

1. Ciocca DR, Fanelli MA (1997) Estrogen receptors and cell proliferation in breast cancer. Trends Endocrinol Metab 8:313-821.
2. Govind AP, Thampan RV (2001) Proteins interacting with the mammalian estrogen receptor: proposal for an integrated model for estrogen receptor mediated regulation of transcription. J Cell Biochem 80:571-579.
3. Fishman J, Osborne MP, Telang NT (1995) The role of estrogen in mammary carcinogenesis. Ann NY Acad Sci 768:91-100.
4. Davidson NE (2000) Combined endocrine therapy for breast cancer-new life for an old idea? J Natl Cancer Inst 92:859-860.
5. Hortobagyi GN (1998) Treatment of breast cancer. N Engl J Med 339:974-984.
6. Chen JD, Evans RM (1995) A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454-457.
7. Heery DM, Kalkhoven E, Hoare S, Parker MG (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733-736.
8. Heinzel T, Lavinsky RM, Mullen TM, Söderstrom M, Laherty CD, Torchia J, Yang WM, Brard G, Ngo SD, Davie JR, Seto E, Eisenman RN, Rose DW, Glass CK, Rosenfeld MG (1997) A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387:43-48.
9. McKenna NJ, Lanz RB, O'Malley BW (1999) Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 2:321-344.
10. Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL, Evans RM (1997) Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373-380.
11. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM (1997) Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569-580.
12. McMahon C, Suthiphongchai T, DiRenzo J, Ewen ME (1999) P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci USA 96:5383-5387.
13. Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, Buisson N, De Witte K, Salandre J, Lenoir G, Pugeat M, Calender A, Parente F, Quincey D, Gaudray P, De Wit MJ, Lips CJ, Höppener JW, Khodaei S, Grant AL, Weber G, Kytölä S, Teh BT, Farnebo F, Phelan C, Hayward N, Larsson N, Pannett AAJ, Forbes SA, Bassett JHD, Thakker RV (1997) Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. Hum Mol Genet 6:1177-1183. (Pubitemid 27308405)
14. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404-407.
15. Sheppherd JJ (1991) The natural history of multiple endocrine neoplasia type 1. Highly uncommon or highly unrecognized? Arch Surg 126:935-952.
16. Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, Edwards CR, Heath DA, Jackson CE, Jansen S, Lips K, Monson JP, O'Halloran D, Sampson J, Shalet SM, Wheeler MH, Zink A, Thakker RV (1996) Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Q J Med 89:653-659.
17. Poisson A, Zablewska B, Gaudray P (2003) Menin interacting proteins as clues toward the understanding of multiple endocrine neoplasia type 1. Cancer Lett 189:1-10.
18. Chandrasekharappa SC, Teh BT (2003) Functional studies of the MEN1 gene. J Intern Med 253:606-615.
19. Agarwal SK, Kennedy PA, Scacheri PC, Novotny EA, Hickman AB, Cerrato A, Rice TS, Moore JB, Rao S, Ji Y, Mateo C, Libutti SK, Oliver B, Chandrasekharappa SC, Burns AL, Collins FS, Spiegel AM, Marx SJ (2005) Menin molecular interactions: insights into normal functions and tumorigenesis. Horm Metab Res 37:369-374.
20. Sayo Y, Murao K, Imachi H, Cao WM, Sato M, Dobashi H, Wong NC, Ishida T (2002) The multiple endocrine neoplasia type 1 gene product, menin, inhibits insulin production in rat insulinoma cells. Endocrinology 143:2437-2440.
21. Schnepp RW, Mao H, Sykes SM, Zong WX, Silva A, La P, Hua X (2004) Menin induces apoptosis in murine embryonic fibroblasts. J Biol Chem 279:10685-10691.
22. Busygina V, Suphapeetiporn K, Marek LR, Stowers RS, Xu T, Bale AE (2004) Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. Hum Mol Genet 13:2399-2408.
23. Jin S, Mao H, Schnepp RW, Sykes SM, Silva AC, D'Andrea AD, Hua X (2003) Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res 63:4204-4210.
24. Scappaticci S, Maraschio P, del Ciotto N, Fossati GS, Zonta A, Fraccaro M (1991) Chromosome abnormalities in lymphocytes and fibroblasts of subjects with multiple endocrine neoplasia type 1. Cancer Genet Cytogenet 52:85-92.
25. Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Burns AL (1999) Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96:143-152.
26. Heppner C, Bilimoria KY, Agarwal SK, Kester M, Whitty LJ, Guru SC, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Burns AL (2001) The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 20:4917-4925.
27. Lin S, Elledge SJ (2003) Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113:881-889.
28. Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A, Biondi CA, Kay GF, Hayward NK, Hess JL, Meyerson M (2004) Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell 13:587-597.
29. Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero DJ, Kitabayashi I, Herr W, Cleary ML (2004) Leukemia protooncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 24:5639-5649.
30. Bhuiyan MM, Sato M, Murao K, Imachi H, Namihira H, Takahara J (2000) Expression of menin in parathyroid tumors. J Clin Endocrinol Metab 85:2615-2619.
31. Bhuiyan MM, Sato M, Murao K, Imachi H, Namihira H, Ishida T, Takahara J, Miyauchi A (2001) Differential expression of menin in various adrenal tumors. The role of menin in adrenal tumors. Cancer 92:1393-1401.
32. Saji S, Okumura N, Eguchi H, Nakashima S, Suzuki A, Toi M, Nozawa Y, Saji S, Hayashi S (2001) MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. Biochem Biophys Res Commun 281:259-265.
33. Sakamoto T, Eguchi H, Omoto Y, Ayabe T, Mori H, Hayashi S (2002) Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. Mol Cell Endocrinol 192:93-104.
34. Murao K, Wada Y, Nakamura T, Taylor AH, Mooradian AD, Wong NC (1998) Effects of glucose and insulin on rat apolipoprotein A-I gene expression. J Biol Chem 273:18959-18965.
35. Murao K, Terpstra V, Green SR, Kondratenko N, Steinberg D, Quehenberger O (1997) Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes. J Biol Chem 272:17551-17557.
36. Hayashi S, Hajiro-Nakanishi K, Makino Y, Eguchi H, Yodoi J, Tanaka H (1997) Functional modulation of estrogen receptor by redox state with reference to thioredoxin as a mediator. Nucleic Acids Res 25:4035-4040.
37. Murao K, Bassyouni H, Taylor AH, Wanke IE, Wong NC (1997) Hepatocyte nuclear factor 4 inhibits activity of site A from the rat apolipoprotein A1 gene. Biochemistry 36:301-306.
38. Namihira H, Sato M, Murao K, Cao WM, Matsubara S, Imachi H, Niimi M, Dobashi H, Wong NC, Ishida T (2002) The multiple endocrine neoplasia type 1 gene product, menin, inhibits the human prolactin promoter activity. J Mol Endocrinol 29:297-304.
39. Dreijerink KM, Mulder KW, Winkler GS, Höppener JW, Lips CJ, Timmers HT (2006) Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res 66:4929-4935.
40. Sato M, Matsubara S, Miyauchi A, Ohye H, Imachi H, Murao K, Takahara J (1998) Identification of five novel germline mutations of the MEN1 gene in Japanese multiple endocrine neoplasia type 1 (MEN1) families. J Med Genet 35:915-919. (Pubitemid 28486619)
41. Berry M, Metzger D, Chambon P (1990) Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811-2818.
42. Shupnik MA, Pitt LK, Soh AY, Anderson A, Lopes MB, Laws ER Jr (1998) Selective expression of estrogen receptor alpha and beta isoforms in human pituitary tumors. J Clin Endocrinol Metab 83:3965-3972.
43. Glass CK, Rose DW, Rosenfeld MG (1997) Nuclear receptor coactivators. Curr Opin Cell Biol 9:222-232.
44. McInerney EM, Tsai MJ, O'Malley BW, Katzenellenbogen BS (1996) Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc Natl Acad Sci USA 93:10069-10073.
45. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965-968.
46. Katzenellenbogen BS, Katzenellenbogen JA (2002) Biomedicine. Defining the "S" in SERMs. Science 295:2380-2381.
47. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS (1996) Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 10:119-131.
48. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG, Rose DW (1998) Diverse signaling pathways modulate nuclear receptor recruitment of NCoR and SMRT complexes. Proc Natl Acad Sci USA 95:2920-2925.
49. Métivier R, Stark A, Flouriot G, Hübner MR, Brand H, Penot G, Manu D, Denger S, Reid G, Kos M, Russell RB, Kah O, Pakdel F, Gannon F (2002) A dynamic structural model for estrogen receptor-alpha activation by ligands, emphasizing the role of interactions between distant A and E domains. Mol Cell 10:1019-1032.
50. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA (2001) Mechanisms of estrogen action. Physiol Rev 81:1535-1565.
51. Norris JD, Fan D, Sherk A, McDonnell DP (2002) A negative coregulator for the human ER. Mol Endocrinol 16:459-468.
52. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB (1997) The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11:693-705.
53. Fox EM, Davis RJ, Shupnik MA (2008) ERbeta in breast cancer-onlooker, passive player, or active protector? Steroids 73:1039-1051.
54. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll J (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456:663-667.
55. Friedl P, Wolf K (2008) Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res 68:7247-7249.
56. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174.
57. Itoh Y (2006) MT1-MMP: a key regulator of cell migration in tissue. IUBMB Life 58:589-596.
58. Kousidou OCh, Berdiaki A, Kletsas D, Zafiropoulos A, Theocharis AD, Tzanakakis GN, Karamanos NK (2008) Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol Oncol 2:223-232.